

Novartis general principles on grants to reputable healthcare (-related) organisations and patient associations.

## Application process and eligibility criteria

### **General principles for all grants**

Novartis may provide funding to external organizations in the interest of driving its mission to improve healthcare, advance scientific knowledge or support the communities where Novartis associates live and work.

Grants are monetary contributions provided by Novartis without intent or agreement to receive any benefit in exchange (a mere display of the Novartis logo or name is not considered a benefit; disclosing Novartis support is important from a transparency perspective, and is not considered a tangible benefit). **In 2020, Grant funding is provided to support patient advocacy related activities.**

Grants are never provided to gain an improper advantage or prompt a favor with funding recipient.

Grants are not intended to interfere with the independent judgment of healthcare organization/ association recipients and/or their associates.

As Novartis only wishes to support actively the grant activity performed by the grant recipient, the grant is not subject to VAT.

Grants will only be given to recognized and reputable patient organizations for the general purpose of supporting healthcare, and this in line with our commitment towards patients and caregivers. In this regard a due diligence on the organization will be undertaken. This may comprise of constitutional documentation, annual reports, web searches or evidence of previous performance or previous direct experience.

Every request for support is subject to a fair review by a dedicated Novartis grant review committee, composed of appropriate Novartis experts, to ensure the acceptability, the non-promotional nature and the independence of the parties. If the outcome of the evaluation process is positive, a contract will be established.

Grant approval is objective and unrelated to any business relationship Novartis has, or may have, with grant requestors.

For transparency reasons it is requested that Novartis funding is disclosed in publications.

After issuance of the grant, you will be requested to provide to Novartis follow-up information about the effective use of the funds for the intended project.

### **Submission requirements**

In order to be considered, a complete grant application package must be submitted to Novartis prior to the activity or event start date. Each request will be evaluated on its merits and the value it brings to patient care.

Annually, Novartis defines the disease areas in which grant requests can be considered. The disease areas eligible for funding are aligned with the Novartis mission and strategic research areas. Grants which are not within the identified therapeutic areas of interest (see Areas of Therapeutic Interest) will not be considered.

Grant applications must be submitted through the GEMS platform ([https://www.cybergrants.com/pls/cybergrants/ao\\_login.login?x\\_gm\\_id=2932&x\\_proposal\\_type\\_id=51678](https://www.cybergrants.com/pls/cybergrants/ao_login.login?x_gm_id=2932&x_proposal_type_id=51678))

### **Grant Requests Not Supported**

- Grants which are not within the identified therapeutic areas of interest (see Areas of Therapeutic Interest)
- Grants to individuals
- Grants for activities which occurred prior to the time of the request. Such grant requests will be immediately deemed ineligible and will be declined.
- Grants to generate income for the grant recipient; grant requests for the funding of materials or services that are invoiced to the patient do not come into consideration.
- Entertainment
- Professional career development (e.g. office/practice management skills, presentation skills, etc.)
- Request for programs that have already started or are in progress
- Activities held in lavish venues/resort locations are strongly discouraged
- Multi-year commitments

### **Areas of Therapeutic Interest and grant amounts**

- Multiple Sclerosis
- Migraine
- Ophthalmology diseases
- Dermatology: psoriasis & urticaria
- Rheumatology: Spondyloarthritides
- Heart Failure
- Clinical Pharmacy
- Breast Cancer
- Melanoma
- Gastric Cancers / NETs
- Lung Cancer
- Malignant Haematology
- Benign Haematology

**In 2020 Novartis Pharma nv will only consider grant requests from Patient Organizations.**

**The amount of the grant awarded, cannot be in excess of 50% of the total project budget. The maximum amount for an individual grant is set at 10 000 €. The Novartis grant review committee has the authority to accept or decline grant requests or ask for additional information. It has the authority to decide on the amount of the grant to be awarded and reserves the right to only partially honor grant requests.**